NX-2127 is a BTK degrader with immunomodulatory capabilities that is undergoing phase 1 clinical trials. NX-2127, which is administered orally, has shown promise in the treatment of chronic lymphocytic leukemia and other B-cell malignancies.
MedKoo Cat#: 130433
Name: NX-2127
CAS#: 2416131-46-7
Chemical Formula: C39H45N9O5
Exact Mass: 719.3544
Molecular Weight: 719.85
Elemental Analysis: C, 65.07; H, 6.30; N, 17.51; O, 11.11
The following data is based on the product molecular weight 719.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
